Login / DE | EN Navigation More about: Partnering Our Partnering Model Areas of Interest Contact Partnering The Grünenthal Group: International, successful, innovative We understand that success can only be achieved through close collaborations with those who share the same vision: to develop innovative medicines for patients with diseases with high unmet needs. We build networks where every party contributes with its expertise and experience – for the mutual benefit and for the benefit of the patients. As a privately owned, mid-sized pharma company, with strong R&D and commercial capabilities, we are well positioned as a partner to bring projects successfully to market. In addition to being a leader in the market for centrally acting analgesics* and having a track record of bringing innovative therapies to patients, we are highly committed to innovation. On average, Grünenthal invests 19% of its revenues into R&D. The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany and present in 32 countries with around 5,500 colleagues working at affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries, and in 2016, Grünenthal achieved revenues of € 1.4 bn. We are looking for: In-licensing or acquisition Rx products / projects in various stages of development (from research to launched products), including medical devices, with potential for game changing innovation In Pain In Pain-related indications like osteoporosis, inflammation, and others, targeting existing customer groups In small / orphan indications like Duchenne or Parkinson, targeting new customer groups who can be served by a small sales force Out-licensing, partnerships or divestments in selected countries at different development stages Maximize value of Grünenthal assets and technologies world-wide Co-promotion/co-marketing agreements for approved products Offering you options for contract manufacturing * Source: Quintiles / IMS 2015 Read our recent press releases on Grünenthal partnering projects Grünenthal enters agreement with AstraZeneca to acquire global rights to migraine treatment Zomig® (Zolmitriptan) The Grünenthal Group announced the acquisition of the company Adhesys Medical to expand its pipeline of medical devices for its business with surgeons Grünenthal to acquire commercialization rights of Qutenza® in Europe from Astellas Pharma Europe Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease Grünenthal and AstraZeneca enter into license agreement for lesinurad in Europe and Latin America Grünenthal announces exclusive license agreement for commercialization of innovative surgical glue in the EU and Latin America Grünenthal Group to Acquire Almirall de Mexico, S.A. de C.V. Grünenthal and Akashi Therapeutics Inc. announce joint drug development program for HT-100 in the treatment of patients with Duchenne Muscular Dystrophy (DMD) Grünenthal GmbH exclusively licenses U.S. and Canadian rights of its innovative analgesic Cebranopadol to Depomed, Inc., confirming their strategic partnership Grünenthal’s Zalviso® 15 micrograms sublingual tablets receives positive CHMP opinion in the EU for treatment of acute moderate to severe post-operative pain in adult patients Grünenthal GmbH granted its consent to the transfer of the license rights for Nucynta® (tapentadol) in the U.S. from Janssen Pharmaceuticals, Inc., to Depomed, Inc. Grünenthal Announces Termination of License Agreement with Actavis for the Development of Cebranopadol as of October 1, 2014 Grünenthal significantly strengthens its pain product portfolio in Europe Grünenthal completes acquisition of Empresas Andrómaco Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO® Grünenthal launches public tender offer to the shareholders of Empresas Andrómaco Grünenthal takes over a product portfolio of BIOGEN® LABORATORIOS The Grünenthal Group Enters into Exclusive Agreement with Horizon Pharma for Commercialization of DUEXIS® in Latin America Partnering Download our brochure Company The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Continue... Products As an R&D focused pharmaceutical corporation, Grünenthal is quite proud of the products from its own development.The portfolio covers a variety of effective treatment options for both chronic and acute pain conditions. Continue... Innovation In Grünenthal Innovation, we are strongly driven to seek new solutions for patients with severe diseases and high unserved medical need – and make these solutions accessible to patients. Continue... Patients As an independent, international, research-based pharmaceutical company we draw on our long-standing experience in innovative pain treatment and development of state-of-the-art technologies to improve patients’ health and quality of life. Continue... Grünenthal's Press Centre In this section you will find both current and archived press releases as well as background information and a selection of images. All of these are downloadable. Continue... Jobs & Career At Grünenthal, we are passionate about improving the quality of life for patients suffering from moderate to severe pain. Discover what makes Grünenthal unique and learn more about our work environment and career opportunities. Continue... You are here: Home // Partnering Overview Company Corporate Executive Board Supervisory Board Facts & Figures Compliance Sustainability Social Responsibility Initiatives History Production Sites Affiliates worldwide Memberships Products Innovation Focus Areas Facts and Figures Innovation Capabilities Partnering & Collaborations Our Pipeline Patients Patient Summit Understanding Pain Definition of Pain Pain Management Grünenthal's Press Centre News Downloads Contact Partnering Our Partnering Model Areas of Interest Contact Jobs & Career Service Contact Grünenthal Worldwide America Europe Grünenthal 2021 © Imprint Privacy Statement Disclaimer General Terms and Conditions